Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

Area of Science:

• Epigenetics and Cancer Therapeutics
• Pharmacology and Drug Design

Background:

• Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator implicated in tumor progression.
• EZH2 inhibitors are investigated as anti-cancer agents, but single-target approaches face challenges like drug resistance.
• Dual-target inhibition strategies offer potential for improved therapeutic outcomes.

Purpose of the Study:

• To review recent advancements in dual inhibitors targeting EZH2 and other proteins.
• To emphasize the rational design, structure-activity relationships, and safety profiles of these dual inhibitors.
• To assess the clinical potential of dual EZH2-targeting agents.

Main Methods:

• Literature review of recent studies on dual EZH2 inhibitors.
• Analysis of rational drug design principles for dual-target agents.
• Evaluation of structure-activity relationships (SAR) and safety data.

Main Results:

• Dual inhibitors targeting EZH2 in combination with BRD4, PARP1, or EHMT2 demonstrate enhanced anti-tumor efficacy.
• Specific examples like EZH1/2 inhibitor HH-2853 showcase improved therapeutic profiles.
• These dual-target strategies show promise in overcoming resistance and reducing side effects.

Conclusions:

• Dual inhibitors targeting EZH2 represent a promising next generation of cancer therapeutics.
• Further research into rational design and clinical evaluation is warranted.
• These agents hold significant potential for clinical application in oncology.